GORDON B. MILLS, MD, PHD
Medical Practice at Holcombe Blvd, Houston, TX

2007019, Aug 16, 2007

Dec 6, 2006

11/634620

Natalia Iartchouk - Wayland MA, US
Mark Ayers - Pennington NJ, US
Jeffrey Brown - Arlington MA, US
Robert Bast - Houston TX, US
Karen Lu - Houston TX, US
Gordon Mills - Houston TX, US

MILLENNIUM PHARMACEUTICALS, INC. - Cambridge MA
Board of Regents, The University of Texas System - Austin TX

C12Q 1/68, G01N 33/574, C12N 5/06, C07K 16/30

435006000, 435007230, 435338000, 530388800

The present invention is directed to the identification of markers that can be used to determine whether tumors are sensitive or resistant to a therapeutic agent. The present invention is also directed to the identification of therapeutic targets. The invention features a number of “sensitivity markers.” These are markers that are expressed in most or all cell lines that are sensitive to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are resistant to treatment with that agent. The invention also features a number of “resistance markers.” These are markers that are expressed in most or all cell lines that are resistant to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are sensitive to treatment with that agent.

2012014, Jun 7, 2012

Nov 4, 2011

13/289230

Edwin Clark - Pennington NJ, US
Tallessyn Grenfell-Lee - Cambridge MA, US
Karen Lu - Houston TX, US
Lynn Hartmann - Rochester NY, US
Jeffrey L. Brown - Arlington MA, US
Gordon B. Mills - Houston TX, US

Millennium Pharmaceuticals, Inc. - Cambridge MA
Mayo Foundation for Medical Education and Research - Rochester MN
Board of Regents, The University of Texas System - Austin TX

C40B 30/04, A61K 33/24, A61P 35/00, A61K 31/337

424649, 506 9, 514449

The present invention is directed to the identification of markers that can be used to determine whether tumors are sensitive or resistant to a therapeutic agent. The present invention is also directed to the identification of therapeutic targets. The invention features a number of “sensitivity markers.” These are markers that are expressed in most or all cell lines that are sensitive to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are resistant to treatment with that agent. The invention also features a number of “resistance markers.” These are markers that are expressed in most or all cell lines that are resistant to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are sensitive to treatment with that agent. The invention also features marker sets that can predict patients that are likely to respond or not to respond to an agent.

2013010, Apr 25, 2013

Sep 28, 2012

13/629973

Millennium Pharmaceuticals, Inc. - Cambridge MA, US
Gordon B. Mills - Houston TX, US
Gabriel N. Hortobagyi - Bellaire TX, US

Board of Regents, The University of Texas System - Austin TX
Millennium Pharmaceuticals, Inc. - Cambridge MA

G01N 33/68

506 9, 435 611, 4353201, 435 612, 435325, 435348, 4352542, 435 79, 536 235, 530350, 5303879

The invention relates to newly discovered nucleic acid molecules and proteins associated with breast or ovarian cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast or ovarian cancers are provided.

7494775, Feb 24, 2009

Mar 11, 2005

11/080991

Ole Petter Veiby - Westborough MA, US
Gordon B. Mills - Houston TX, US
Gabriel N. Hortobagyi - Bellaire TX, US

Millennium Pharmaceuticals, Inc. - Cambridge MA
UT Board of Regents - Austin TX

C12Q 1/68

435 6, 435 911, 536 231

The invention relates to newly discovered nucleic acid molecules and proteins associated with breast or ovarian cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast or ovarian cancers are provided.

7670767, Mar 2, 2010

Aug 4, 1997

08/905508

Laleh Shayesteh - Foster City CA, US
Joe W. Gray - San Francisco CA, US
Gordon B. Mills - Houston TX, US
Yiling Lu - Houston TX, US

The Regents of the University of California - Oakland CA
Board of Regents, The University of Texas System - Austin TX

C12Q 1/68

435 6, 514 2

The present invention provides new probes for the detection of chromosomal alterations associated with cancer, particularly ovarian cancer. The probes bind selectively with target nucleic acid sequences at 3q26.

2002018, Dec 5, 2002

Nov 8, 2001

10/035415

James Lillie - Natick MA, US
Gordon Mills - Houston TX, US
John Lee - Somerville MA, US

Millennium Pharmaceuticals, Inc. - Boston MA

C12Q001/68, G01N033/574

435/006000, 435/007230

The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating human ovarian cancers. A variety of markers are provided, wherein changes in the levels of expression of one or more of the markers is correlated with the presence of ovarian cancer.

2002015, Oct 17, 2002

Jun 4, 2002

10/164139

Gordon Mills - Houston TX, US
Bruce Holub - Ontario, CA
Douglas Gaudette - Ontario, CA

G01N033/574, G01N033/48

435/007230, 436/064000

The present invention is methods for detecting the presence of cancer in a subject by determining the concentrations of lysophospholipids in a sample of bodily fluid taken from a test subject and comparing these concentrations to concentrations present in samples taken from normal subjects without cancer. The methods may be used for diagnosis and prognosis of cancer in a subject and to monitor the results of therapy of over time.

2008007, Mar 20, 2008

Dec 15, 2004

10/598216

Yutaka Hasegawa - Odawara, JP
Gordon Mills - Houston TX, US

THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM - Austin TX

C07F 9/09

568 12, 568 15

p-00010000